Panchsheel Organics Limited Submits SEBI Compliance Certificate for Q4 FY26

1 min read     Updated on 12 Apr 2026, 03:20 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Panchsheel Organics Limited filed its SEBI Regulation 74(5) compliance certificate for Q4 FY26 on April 09, 2026. The certificate, processed through registrar Purva Sharegistry, confirms proper handling of 1,900 dematerialised shares across five transactions between January and March 2026. All securities were confirmed to depositories within prescribed timelines, with certificates properly mutilated and cancelled after verification, demonstrating regulatory compliance.

powered bylight_fuzz_icon
37533028

*this image is generated using AI for illustrative purposes only.

Panchsheel Organics Limited has submitted its compliance certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter and financial year ended March 31, 2026. The certificate was filed with BSE Limited on April 09, 2026, through the company's registrar and share transfer agent, Purva Sharegistry (I) Pvt. Ltd.

Regulatory Compliance Confirmation

The certificate confirms that all securities received from depository participants for dematerialisation during the quarter ended March 2026 were properly processed and confirmed to the depositories. Purva Sharegistry, acting as the compliance officer, verified that all security certificates received for dematerialisation were confirmed or rejected within the prescribed timelines.

Dematerialisation Activity Details

During the period from January 01, 2026 to March 31, 2026, the company processed five dematerialisation transactions involving a total of 1,900 shares:

Shareholder Certificate No. Share Quantity Dematerialisation Date
Atul Shah 0052018 500 20/01/2026
Atul Harsukhlal Shah 0052021 100 11/02/2026
Atul H Shah 0052020 500 27/02/2026
Tarla Pankaj Lapasia 0052196 400 04/03/2026
Tarla Pankaj Lapasia 0052460 400 04/03/2026

Process Verification

The registrar confirmed that all security certificates received were properly mutilated and cancelled after due verification by the depository participant. The names of the depositories have been substituted in the register of members as the registered owner within the prescribed timelines, ensuring compliance with SEBI regulations.

Company Information

Panchsheel Organics Limited, a manufacturer of bulk drugs and formulations, operates from its corporate office in Andheri East, Mumbai. The company's Managing Director, Mahendra Abhaychand Turakhia, signed the compliance submission to BSE Limited. The certificate demonstrates the company's adherence to regulatory requirements for share dematerialisation processes during the quarter.

Historical Stock Returns for Panchsheel Organics

1 Day5 Days1 Month6 Months1 Year5 Years
+0.58%+4.79%+6.16%-19.91%-26.73%+146.45%

Will the concentration of dematerialisation activity among just two shareholders signal potential changes in Panchsheel Organics' ownership structure?

How might the company's transition to increased dematerialised holdings affect its trading liquidity and market accessibility?

What impact could enhanced regulatory compliance have on Panchsheel Organics' ability to attract institutional investors in the pharmaceutical sector?

Panchsheel Organics Declares ₹0.80 Interim Dividend with Record Date February 20

2 min read     Updated on 14 Feb 2026, 11:46 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Panchsheel Organics Limited has declared an interim dividend of ₹0.80 per share following its board meeting on February 14, 2026, representing 8% of paid-up share capital with record date set for February 20, 2026. The company reported Q3FY26 revenue of ₹2,673.20 lakh and net profit of ₹367.75 lakh, showing modest growth compared to the previous year.

powered bylight_fuzz_icon
32344887

*this image is generated using AI for illustrative purposes only.

Panchsheel Organics Limited has officially declared an interim dividend of ₹0.80 per share following its board meeting held on February 14, 2026. The pharmaceutical company, which manufactures bulk drugs and formulations, announced the dividend declaration under Regulation 30 and 42 of SEBI (LODR) Regulations, 2015.

Dividend Declaration Details

The board meeting, conducted from 4:00 p.m. to 5:10 p.m., resulted in the approval of interim dividend for the quarter and nine months ended December 31, 2025. The dividend represents 8% of the company's paid-up share capital, demonstrating the management's commitment to shareholder returns.

Dividend Parameters: Details
Interim Dividend: ₹0.80 per share
Face Value: ₹10.00 per share
Percentage of Paid-up Capital: 8%
Record Date: Friday, February 20, 2026
Payment Timeline: Within 30 days of declaration

Financial Performance Highlights

The company reported steady financial performance for Q3FY26, with revenue from operations reaching ₹2,673.20 lakh compared to ₹2,624.39 lakh in Q3FY25. Net profit for the quarter stood at ₹367.75 lakh, showing marginal improvement from ₹366.89 lakh in the corresponding previous quarter.

Financial Metrics: Q3FY26 (₹ Lakh) Q3FY25 (₹ Lakh) Change
Revenue from Operations: 2,673.20 2,624.39 +1.86%
Total Income: 2,779.10 2,719.89 +2.18%
Net Profit: 367.75 366.89 +0.23%
Earnings Per Share: ₹2.79 ₹2.79 -

Regulatory Compliance and Timeline

The dividend declaration was made in compliance with SEBI regulations, with the company setting Friday, February 20, 2026, as the record date for determining shareholder entitlement. The payment of interim dividend will be completed within the regulatory timeline of 30 days from the declaration date.

Regulatory Details: Information
BSE Scrip Code: 531726
Security Type: Equity Shares
Record Date: Friday, February 20, 2026
Declaration Date: February 14, 2026
Payment Deadline: Within 30 days

Nine-Month Performance Overview

For the nine months ended December 31, 2025, the company reported total income of ₹7,797.83 lakh compared to ₹8,187.75 lakh in the corresponding period of the previous year. The net profit for the nine-month period stood at ₹912.84 lakh, reflecting the company's consistent operational performance in the pharmaceutical manufacturing sector.

Historical Stock Returns for Panchsheel Organics

1 Day5 Days1 Month6 Months1 Year5 Years
+0.58%+4.79%+6.16%-19.91%-26.73%+146.45%

More News on Panchsheel Organics

1 Year Returns:-26.73%